biotechnology

Non-Invasive electrophysiological monitoring of cardiac organoids using 3D-Net-assisted microelectrodes array platform

by

The Future of Heart Health: How Organoids and Bioelectronics are Revolutionizing Cardiac Research For decades, testing the safety and efficacy of new drugs on the heart relied heavily on animal models and, increasingly, limited human cell cultures. But a paradigm shift is underway. Researchers are increasingly turning to human heart organoids – miniature, 3D recreations … Read more

Insurers Blame Drugmakers & Hospitals for Rising Health Care Costs | STAT News

by

The Shifting Sands of Healthcare Costs: A Look at Insurer, Hospital, and Drugmaker Dynamics The U.S. healthcare system is perpetually under scrutiny for its soaring costs. Recent Congressional hearings have highlighted a familiar blame game, with health insurers pointing fingers at hospitals and pharmaceutical companies. But this isn’t just about assigning fault; it’s a signal … Read more

Personalized supervised and unsupervised intracranial sleep decoding during deep brain stimulation

by

The Future of Parkinson’s Care: Decoding Sleep to Unlock Better Treatments For years, Parkinson’s disease has been primarily understood through the lens of motor symptoms – tremors, rigidity, and slowness of movement. However, a growing body of research, fueled by advancements in neurotechnology and data science, is revealing a crucial, often overlooked dimension: sleep. And … Read more

Novo Nordisk, Pfizer execs weigh in

by

The Shifting Sands of Pharma: Navigating Patent Cliffs, Deals, and a New Political Landscape The pharmaceutical industry entered 2026 with a cautious optimism, a sentiment echoing from the recent JPMorgan Healthcare Conference in San Francisco. While geopolitical uncertainties lingered in 2025, a potential turning point for the sector is on the horizon, fueled by falling … Read more

Trump Health Plan & FDA Delays: Biotech News Roundup

by

The Shifting Sands of Biotech: Trump’s Health Plan, FDA Delays, and Future Trends The biotech landscape is in constant flux, shaped by political winds, regulatory hurdles, and relentless scientific innovation. Recent developments – Donald Trump’s proposed health plan and FDA delays in drug approvals – are just the latest indicators of a sector bracing for … Read more

Pharma & Biotech Moves: New Hires & Executive Changes | STAT News

by

The Revolving Door in Biotech: Why Executive Moves Signal Future Trends The pharmaceutical and biotechnology industries are known for a high degree of executive mobility. A seemingly simple “coming and going” announcement, like the recent hiring of Roger Waltzman as Chief Medical Officer at Biolojic Design (previously at Indaptus Therapeutics), is actually a powerful indicator … Read more

JPM24: Gilead’s Kite Pharma Faces FDA Decision on Myeloma Therapy

by

The Future of CAR-T Therapy: Beyond Multiple Myeloma and Gilead’s Next Moves The recent news regarding Gilead’s submission of anito-cel, a CAR-T therapy for multiple myeloma developed in partnership with Arcellx, isn’t just a single data point. It’s a flashing signal illuminating the evolving landscape of CAR-T (Chimeric Antigen Receptor T-cell) therapy and the broader … Read more

FDA Delays Stoke Therapeutics’ Epilepsy Drug Review Path

by

The FDA’s Shifting Stance on Expedited Drug Approval: A Biotech Turning Point? The recent snag between Stoke Therapeutics and the FDA regarding accelerated approval for zorevunersen, a potential treatment for Dravet syndrome, isn’t an isolated incident. It signals a potentially significant shift in how the agency evaluates novel therapies, particularly those utilizing innovative approaches like … Read more

Alnylam 2030: Gene-Silencing Firm Outlines Next 5 Years of Growth & Innovation | STAT+

by

Alnylam’s Bold Vision: Gene Silencing and the Future of Biotech Alnylam, a pioneer in RNA interference (RNAi) therapeutics, recently unveiled its “Alnylam 2030” plan, signaling a continued commitment to innovation and ambitious growth. While recent quarterly sales of its flagship drug, Amvuttra, slightly missed expectations, the company’s long-term outlook remains remarkably optimistic. This isn’t just … Read more

JPM Week: Biotech’s Biggest Meeting Isn’t Everything

by

Beyond JPM Week: The Evolving Biotech Landscape The future of biotech extends far beyond the annual JPM Healthcare Conference.The annual JPM Healthcare Conference in San Francisco is a pivotal moment for the biopharmaceutical industry, a concentrated burst of deal-making and networking. But as Adam Feuerstein rightly points out, the engine of biotech innovation doesn’t pause … Read more

© 2026 Newsy Today. All rights reserved.


For contact, advertising, copyright, issues email: [email protected]

For contact, advertising, copyright, issues email: [email protected]